Merck and Moderna Release Full Phase 3 mRNA Cancer Vaccine Data for Melanoma

Merck and Moderna have released full data from a Phase 3 trial of their personalized mRNA cancer vaccine for melanoma after partial results leaked. The report explains the trial results when the vaccine is combined with Keytruda, including reductions in recurrence or death and in distant metastasis or death, and notes discussions with regulators. It also provides context for interpreting the market reaction and analyst expectations.

■ Trial data and clinical findings
- Full Phase 3 results for the mRNA-based cancer vaccine in melanoma
- Combination with Merck’s Keytruda versus Keytruda alone
- Reported 42% reduction in risk of recurrence or death
- Reported 38% reduction in risk of distant metastasis or death

■ Context and next steps
- Earlier partial leak and planned presentation at a Madrid oncology conference
- Analyst expectations and stock pressure around the announcement
- Company characterization of the data and regulatory discussions

The report is suited to viewers following oncology trial updates, mRNA therapeutics, or biotech market news. It provides a concise overview of the disclosed results and the surrounding context, helping viewers understand what was announced and what questions remain as regulatory review proceeds.